Verdinexor (KPT-335) is primarily investigated for its potential in treating various cancers. It works by inhibiting the export of tumor suppressor proteins and growth regulatory proteins from the nucleus to the cytoplasm, which can help in reducing cancer cell proliferation. This mechanism makes it a promising candidate for cancers that are resistant to conventional therapies, such as certain types of lymphoma and sarcoma.

In veterinary medicine, Verdinexor has shown efficacy in treating canine cancers, particularly lymphoma. Its ability to selectively target cancer cells while sparing normal cells offers a significant advantage in managing the disease with fewer side effects compared to traditional chemotherapy.

Additionally, Verdinexor is being explored for its antiviral properties. Research indicates it can inhibit the replication of certain viruses by blocking the nuclear export of viral RNA, making it a potential therapeutic option for viral infections, including influenza and SARS-CoV-2.

Overall, Verdinexor represents a versatile compound with applications in oncology and virology, offering new avenues for treatment in both human and veterinary medicine.